BIAF
bioAffinity Technologies, Inc. (NASDAQ)
Healthcare — Diagnostics & Research
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Price History
Fundamentals
| Market Cap | $5.30M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.41 |
| EPS (TTM) | $-4.67 |
| Dividend Yield | - |
| Profit Margin | -280.57% |
| Revenue Growth | -27.10% |
| ROE | -622.65% |
| Debt/Equity | 37.76 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 18.4 |
| Beta | -1.34 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.50 |
| 52-Week Low | $0.69 |
| 50-Day Avg | $1.67 |
| 200-Day Avg | $2.08 |
| Avg Volume | 420.1K |
| Volume | 290.5K |
Performance Analysis
NEUTRALBIAF presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 12:59 UTC
Back to Screener Export Report